Building the future of biohardware for bone health

Worldwide, several million people living with prostate, breast or lung cancer will develop bone metastases and suffer fractures or other skeletal-related events.

Today, clinicians rely on imaging, which only detects bone damage once it is already advanced. Our solution enables earlier treatment decisions for high-risk patients.

We expose patient-derived blood cells to our biohardware, a 3D-bioprinted, mineralized living bone model and measure how those cells weaken the model. This provides a direct functional biological readout, rather than an indirect signal, such as imaging or sequencing.